Description General description A cell-permeable triazine based compound that inhibits Ca2+-dependent fusion of lysosomes with the plasma membrane and the release of lysosomal content, without affecting enlargeosomes or other membrane-bound organelles. It does not disturb the organization of the actin or tubulin cytoskeletal network, nor does it interfere with membrane traffic along the constitutive pathway from the ER to the plasma membrane. A cell-permeable triazine-based compound that inhibits Ca2+-dependent exocytosis of lysosomes induced by ionomycin or plasma membrane wounding. Does not affect the resealing process and the exocytosis of enlargeosomes. It also does not disturb the organization of the actin or tubulin cytoskeletal network or interfere with membrane traffic along the constitutive pathway from the ER to the plasma membrane. Packaging 10 mg in Glass bottle Biochem/physiol Actions Cell permeable: yes Primary Target Ca2+-dependent fusion of lysosomes with the plasma membrane Product does not compete with ATP. Reversible: no Packaging Packaged under inert gas Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. Other Notes Cerny, J., et al. 2004. EMBO Rep.5, 883.